Pseudorapidity Distributions Study for Fast Target Protons Produced in the Interactions of \(^{84}\)Kr with Emulsion at 1 GeV per Nucleon
Acta Physica Polonica B · 28.05.2026 · 57 (7) · 1
DOI: 10.5506/aphyspolb.57.7-a1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Physica Polonica B, online erschienen am 28.05.2026. Verfasst von M.K. Singh. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The study of the process of particle creation in high-energy nucleon–nucleon and nucleus–nucleus collisions heavily relies on the pseudorapidity distribution (PD) of charged particles. Several theoretical theories and concepts may frequently be tested using the multiplicity distributions (MD) and PD of final-state particles. In this work, we have utilized PD to investigate potential processes that might produce the fast target protons (FTP) released from the interactions of \(^{84}\mathrm {Kr}\) with emulsion at 1 \(A\) GeV. In order to examine the properties of the FTP emitted system for various targets (such as AgBr, CNO, and Em) of the nuclear emulsion detector (NED), the angular distribution (AD) and PD of the generated FTP were examined. Abstract Published by the Jagiellonian University 2026 authors
Zitieren
APA
Singh, M. (2026). Pseudorapidity Distributions Study for Fast Target Protons Produced in the Interactions of \(^{84}\)Kr with Emulsion at 1 GeV per Nucleon. Acta Physica Polonica B, 57(7), 1. https://doi.org/10.5506/aphyspolb.57.7-a1
Vancouver
Singh M. Pseudorapidity Distributions Study for Fast Target Protons Produced in the Interactions of \(^{84}\)Kr with Emulsion at 1 GeV per Nucleon. Acta Physica Polonica B. 2026;57(7):1. doi:10.5506/aphyspolb.57.7-a1
BibTeX
@article{Singh2026,
author = {Singh, M.K.},
title = {Pseudorapidity Distributions Study for Fast Target Protons Produced in the Interactions of \(^84\)Kr with Emulsion at 1 GeV per Nucleon},
journal = {Acta Physica Polonica B},
year = {2026},
volume = {57},
number = {7},
pages = {1},
doi = {10.5506/aphyspolb.57.7-a1}
}
EUVIMED